8月14日，用于治疗黄斑变性地图样萎缩的创新药物IZERVAY经港澳药械通政策获批引入大湾区，在深圳希玛林顺潮眼科医院完成了内地首位患者的给药注射[1]。
接受治疗的患者情况备受关注。该患者治疗前左眼已看不见，右眼视力仅为0.3[1]。经过5针IZERVAY治疗后，患者右眼视力恢复并稳定在0.5[1]。林顺潮教授指出，过去临床上对地图样萎缩患者仅能进行随访观察与低视力康复，缺乏有效的治疗手段[1]。
从患病规模看，这一新疗法的引入意义重大。我国年龄相关性黄斑变性患者超过4000万，患病率约为0.5%-1%，其中约有20万至40万人受地图样萎缩影响[1]。港澳药械通政策为内地患者提供了国际同标准的治疗方案。目前，希玛医疗集团旗下的珠海、深圳、广州、惠州4家医院已成为港澳药械通指定医疗机构[1]。
An innovative therapeutic agent for treating geographic atrophy associated with age-related macular degeneration has been approved for use in the Greater Bay Area through the Hong Kong-Macau pharmaceutical and medical device policy, with the first mainland patient receiving treatment at Shenzhen Aier Shima Lin Shun Chao Eye Hospital on August 14 [1]. The medication, IZERVAY, marks a significant milestone in expanding access to international-standard treatment options for regional patients [1].
The treated patient demonstrated substantial clinical improvement following the intervention [1]. Prior to receiving IZERVAY therapy, the patient had complete vision loss in the left eye and reduced visual acuity of 0.3 in the right eye [1]. After undergoing five injections of the treatment, the patient's right eye vision recovered and stabilized at 0.5 [1]. According to clinical leadership, this represents a meaningful advancement, as previous management approaches were limited to observation and low-vision rehabilitation without effective therapeutic interventions [1].
The scale of the clinical need underscores the significance of this development [1]. Age-related macular degeneration affects more than 40 million patients in China, with a disease prevalence of approximately 0.5% to 1% [1]. Between 200,000 and 400,000 individuals are affected by the geographic atrophy subtype specifically [1]. Shima Healthcare Group operates four designated medical institutions participating in the Hong Kong-Macau pharmaceutical and medical device policy across Zhuhai, Shenzhen, Guangzhou, and Huizhou, positioning these facilities to broaden patient access to such innovative therapies [1].
